Skip to main content

Increased frequency of rapid acetylator genotypes in patients with brain astrocytoma and meningioma

Buy Article:

$43.00 plus tax (Refund Policy)

Olivera M, Martínez C, Molina JA, Alonso-Navarro H, Jiménez-Jiménez FJ, García-Martín E, Benítez J, Agúndez JAG. Increased frequency of rapid acetylator genotypes in patients with brain astrocytoma and meningioma.

Acta Neurol Scand 2006: 113: 322–326.

© 2006 The Authors Journal compilation © 2006 Blackwell Munksgaard. Objectives – 

The arylamine N-acetyltransferase (NAT2) is a polymorphic enzyme involved in deactivation and activation of carcinogens through N- and O-acetylation. We investigated the association between the genetic NAT2 polymorphism and brain tumors by analysis of genomic DNA from 71 brain tumor patients and 258 healthy controls. Materials and methods – 

Seven single nucleotide polymorphisms of the NAT2 gene were studied by using allele-specific polymerase chain reaction amplification. Results – 

Ten different NAT2 allelic variants were identified in both patient and control groups. A higher number of individuals carrying functional NAT2 genes, and therefore with a rapid acetylation phenotype, was found in brain tumor patients vs healthy volunteers (OR 1.79, 95% CI 1.05–3.05; P < 0.05). This is observed either for patients suffering from meningioma or astrocytoma, and this is due to an increase of the wild-type NAT2*4 allelic variant frequency (OR 1.48, 95% CI 0.99–2.19), and a reduction of the commonest defective allelic variant NAT2*5B in the brain tumor patients, compared with healthy subjects (OR 0.54, 95% CI 0.37–0.80). Conclusions – 

This observation indicates that NAT2 could be considered as a low-penetrance gene for brain tumors, and that individuals carrying rapid acetylation alleles are at increased risk of developing brain tumors.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: NAT2; acetylation; brain tumor; polymorphisms

Document Type: Research Article

Affiliations: 1: Department of Pharmacology, Medical School, University of Extremadura, Badajoz, Spain 2: Service of Neurology, University Hospital Doce de Octubre, Madrid, Spain 3: Department of Medicine-Neurology, University Hospital Principe de Asturias, Madrid, Spain 4: Department of Biochemistry & Molecular Biology, School of Sciences, University of Extremadura, Badajoz, Spain

Publication date: 2006-05-01

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more